As of January 2019, there were an estimated 16.9 million cancer survivors in the United States: this is driving growth of the BRAF kinase inhibitors market

The growing prevalence of cancer coupled with the robust pipeline for the treatment of metastatic cancers is driving the growth of the BRAF kinase inhibitors market. According to the National Cancer Institute, cancer is among the leading causes of death worldwide. In 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million. Moreover, several clinical trials around the globe for developing novel drugs for cancer treatment are again anticipated to propel the growth of the market. For instance, in June 2020, BeiGene, Ltd., and SpringWorks Therapeutics, Inc., announced the presentation of preclinical data and provided a program update on their ongoing Phase 1b/2 study evaluating the combination of BeiGene’s investigational RAF dimer inhibitor, lifirafenib, with SpringWorks’ investigational MEK inhibitor, trametinib, in patients with advanced or refractory solid tumors harboring mutations in the MAPK pathway, including those with RAS mutations.'

Key players operating in the global BRAF kinase inhibitors market include F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.

North America is expected to dominate the global BRAF kinase inhibitors market and this can be accredited to the high prevalence of cancer in the region. As of January 2019, there were an estimated 16.9 million cancer survivors in the United States. The number of cancer survivors is projected to increase to 22.2 million by 2030. Estimated national expenditures for cancer care in the United States in 2018 were $150.8 billion.

BRAF Kinase Inhibitors has proven to be extremely effective in treating the illnesses that are caused by the inhibition of the activity of the proteinase called Apoenzyme Q. These inhibitors are usually prescribed to patients after they have achieved clinical independence.

1. In July 2020, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor atezolizumab (Tecentriq) plus the MEK inhibitor cobimetinib (Cotellic) and the selective BRAF kinase inhibitor vemurafenib (Zelboraf) for the treatment of patients with advanced BRAF V600 mutation-positive melanoma. The approval is based on results from IMspire150, a multicenter, double-blind, placebo-controlled randomized phase III study.
2. In April 2020, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAFV600E mutation, as detected by an FDA-approved test, after prior therapy